Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report

Prasanna, Rammohan; Bunger, Deepak; Khan, Mubeen

doi:10.3892/mco.2017.1519

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy and safety of NDLS has been demonstrated in breast, gastric, ovarian, cervical, penile, hormone refractory prostate and non-small cell lung cancers. 21,[28][29][30][31] Furthermore, a panel of oncology experts has recommended using NDLS in patients with metastatic disease, those at risk of hypersensitivity reactions, diabetics and those in whom steroids need to be avoided. 32 The current study presents the findings of NDLS-based chemotherapy in breast cancer patients in neoadjuvant, adjuvant and metastatic settings.…”

Section: Discussionmentioning

confidence: 99%

Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study

Subramanian

Prasanna²,

Biswas

et al. 2020

BCTT

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip)-based chemotherapy in breast cancer. Methods: Medical charts of patients with breast cancer, who were treated and followed up with NDLS (75-100 mg/m 2 ; 3-week cycle)-based chemotherapy from August 2014 to September 2018, were analyzed in this multicenter, retrospective study. The study endpoints were overall response rate (ORR: complete response [CR]+partial response [PR]) and disease control rate (DCR: CR+PR+stable disease [SD]) in neoadjuvant and metastatic settings. Overall survival (OS) and safety were evaluated for all settings. Results: Of 91 patients (neoadjuvant: 12, adjuvant: 61, metastatic: 18), efficacy evaluation in 29 patients (neoadjuvant: 12/12, metastatic: 17/18) demonstrated an ORR and DCR of 100%, respectively, in the neoadjuvant setting, and an ORR of 64.7% and DCR of 70.6%, respectively, in the metastatic setting. At a median follow-up of 21.6 months (range: 2.1 to 49.9 months), median OS was not reached in neoadjuvant and adjuvant settings, and it was 30.4 months in metastatic settings. At least one adverse event (AE) was reported in 59.3% of patients. Anemia, thrombocytopenia, lymphopenia, and neutropenia were the most common hematological AEs reported while hyperglycemia and alteration in liver function tests were the most common non-hematological AEs. NDLS-based treatment was well tolerated without any new safety concerns. Conclusion: Nanosomal docetaxel lipid suspension-based chemotherapy was efficacious and well tolerated in the treatment of breast cancer. Further, NDLS is being evaluated prospectively in patients with triple-negative breast cancer (ClinicalTrials.gov: NCT03671044).

show abstract

Section: Discussionmentioning

confidence: 99%

Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study

Subramanian

Prasanna²,

Biswas

et al. 2020

BCTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efficacy and tolerability of DoceAqualip has been demonstrated in comparison with conventional docetaxel in the treatment of breast cancer [21]. Furthermore, DoceAqualip has shown a promising overall response and tolerability without the need of corticosteroid premedication in the treatment of breast cancer, advanced gastric adenocarcinoma, ovarian cancer, cervical cancer, hormone refractory prostate cancer, and non-small cell lung cancer [21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Novel Docetaxel Formulation (NDLS) in Low Cardiac Reserve Ovarian Cancer

Vyas¹

2018

OAJCO

View full text Add to dashboard Cite

Ovarian cancer in patients with a history of breast carcinoma is not uncommon. We report here a case of successful management of a patient with ovarian cancer with omental tissue metastasis in a 40-year-old woman having poor ejection fraction with a prior history of breast cancer. The patient presented with enlarged ovaries with solid cystic masses suggestive of poorly differentiated metastatic carcinoma. In view of poor ejection fraction (heart failure) in the ovarian cancer patient, nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) in combination with carboplatin was used in a neoadjuvant setting followed by surgical resection. This is the first such case report showing the successful treatment of carcinoma of ovary, with omental tissue metastasis, with DoceAqualip in a neoadjuvant setting followed by bilateral salpingo-oophorectomy in a patient having heart failure with a prior history of breast carcinoma.

show abstract

“…Overall, after two years of follow-up, the patient did not develop any recurrence carcinoma, suggesting NDLS to be an excellent anticancer agent. 86…”

Section: Docetaxel-loaded Nano-pharmaceutical [Crlx301]mentioning

confidence: 99%

Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use

Dhupal¹,

Chowdhury²

2020

IJN

View full text Add to dashboard Cite

Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report

Cited by 10 publications

References 19 publications

<p>Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study</p>

<p>Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study</p>

Novel Docetaxel Formulation (NDLS) in Low Cardiac Reserve Ovarian Cancer

<p>Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use</p>

Contact Info

Product

Resources

About